Prevention of post liver transplant HBV recurrence

[Guest guest]

http://www.springerlink.com/content/g38w375828j06607/

Hepatology International

DOI: 10.1007/s12072-011-9293-8Online First™

Review Article

Prevention of post liver transplant HBV recurrence

Geoffrey W. McCaughan

Abstract

Background

Twenty years ago, liver transplantation for hepatitis B had been a relative

contraindication to universal HBV recurrence and poor outcomes. Over the ensuing

two decades, there has been refinement of prevention strategies in order to

minimize HBV recurrence in the allograft.

Results

Currently, the most efficacious and cost-effective strategies include newer oral

antiviral drugs in combination with low doses of hepatitis B immunoglobulin

(HBIG). More recently, strategies have been successful in withdrawing HBIG and

newer approaches of HBIG avoidance are currently under development.

Conclusion

Thus, 20 years afterward, HBV recurrence is <5% and outcomes following liver

transplantation are excellent.